Next Day Disclosure Return
Filed with HKEX · Stock code 2096 · · 8 pages · English
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- Voluntary announcement - the clinical trial approval for SIM0725 (CD122) issued by the national medical products administration
- Voluntary announcement - the clinical trial approval for SIM0709 (TL1A/il-23P19 bispecific antibody) issued by the german regulatory authority and ethics committee
- Voluntary announcement - new drug application (nda) of zemprocitinib for the treatment of rheumatoid arthritis was accepted by the national medical products administration
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - entering into an exclusive promotion services agreement with lynk pharmaceuticals in respect of dermatological indications of zemprocitinib
Later from Simcere Pharmaceutical
- Voluntary announcement - inclusion of Sanbexin sublingual tablets into the new national reimbursement drug list
- Voluntary announcement - the clinical trial approval for SIM0712 (STAT6) issued by the national medical products administration
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical